Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 3/20 | 0.57 |
| ▸ | NPY2R | P49146 | 3/20 | 0.57 |
| ▸ | NPY4R | P50391 | 3/20 | 0.57 |
| ▸ | GHSR | Q92847 | 8/20 | 0.57 |
| ▸ | CCKBR | P32239 | 2/20 | 0.56 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.56 |
| ▸ | MC4R | P32245 | 2/20 | 0.53 |
| ▸ | MC5R | P33032 | 1/20 | 0.53 |
| ▸ | MC3R | P41968 | 1/20 | 0.53 |
| ▸ | MC1R | Q01726 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30618455 | 1.00 | NPY1R (0.57) | NPY1RNPY2RNPY4RGHSRCCKBR | |
| SCHEMBL29519296 | 0.95 | KISS1R (0.60) | NPY1RNPY2RNPY4RGHSRCCKBR | |
| SCHEMBL30366588 | 0.95 | KISS1R (0.60) | NPY1RNPY2RNPY4RGHSRCCKBR | |
| SCHEMBL30494060 | 0.94 | KISS1R (0.60) | NPY1RNPY2RNPY4RGHSRCCKBR | |
| SCHEMBL29399016 | 0.90 | GHSR (0.68) | NPY1RNPY2RNPY4RGHSRKISS1R | |
| SCHEMBL29402231 | 0.90 | GHSR (0.69) | NPY1RNPY2RNPY4RGHSRKISS1R | |
| SCHEMBL29519677 | 0.87 | KISS1R (0.57) | NPY1RNPY2RNPY4RCCKBRKISS1R | |
| SCHEMBL30015333 | 0.85 | REN (0.53) | GHSR | |
| SCHEMBL29373777 | 0.84 | NPY1R (0.74) | NPY1RNPY2RNPY4RKISS1RMC4R | |
| SCHEMBL30051525 | 0.82 | CTSC (0.66) | GHSRCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3523274-B1 | FORMULATIONS FOR ADMINISTRATION OF EFLORNITHINE | ORBUS THERAPEUTICS INC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250041256-A1 | COMPOSITIONS AND METHODS FOR USE OF EFLORNITHINE AND DERIVATIVES AND ANALOGS THEREOF TO TREAT CANCERS, INCLUDING GLIOMAS | ORBUS THERAPEUTICS INC (US) | 2025-02-06 | — | — | US | disclosed |
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2024-11-14 | — | — | US | disclosed |
| CN-117530943-A | Formulations for administration of efluromithine | 奥巴斯治疗股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| US-20230338317-A1 | FORMULATIONS FOR ADMINISTRATION OF EFLORNITHINE | Orbus Therapeutics, Inc. | 2023-10-26 | — | — | US | disclosed |
| US-11541027-B2 | Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2023-01-03 | — | — | US | disclosed |
| CN-115414480-A | Dianhydrogalactitol in combination with radiation for treatment of non-small cell lung cancer and glioblastoma multiforme | 德玛医药 | 2022-12-02 | — | — | CN | disclosed |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
| US-11439612-B2 | Formulations for administration of eflornithine | Orbus Therapeutics, Inc. (US) | 2022-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DCK, CDC7, DNMT1 | NPY1R 4295/4885NPY2R 4149/4885NPY4R 4237/4885 |
| US-20230338317-A1 | FORMULATIONS FOR ADMINISTRATION OF EFLORNITHINE | EFNA1, IDH1, ABCC5 | NPY1R 4697/4885NPY2R 4790/4885NPY4R 4861/4885 |
| US-11439612-B2 | Formulations for administration of eflornithine | EFNA1, KMT5A, ETV1 | NPY1R 4340/4885NPY2R 4587/4885NPY4R 4735/4885 |
| US-11541027-B2 | Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases | DNMT1, MGMT, DCK | NPY1R 4864/4885NPY2R 4836/4885NPY4R 4823/4885 |
| US-20250041256-A1 | COMPOSITIONS AND METHODS FOR USE OF EFLORNITHINE AND DERIVATIVES AND ANALOGS THEREOF TO TREAT CANCERS, INCLUDING GLIOMAS | AHCY, SRM, SHMT1 | NPY1R 4842/4885NPY2R 4865/4885NPY4R 4884/4885 |
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | NPY1R 65/4885NPY2R 129/4885NPY4R 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.